
Objective: To evaluate the agreement between direct gradient diffusion (DGD), performed directly from positive blood culture bottles, and the Sensititre'" YeastOne'" (SYO) method for antifungal susceptibility testing in Candida spp. Methods: A prospective observational study including blood cultures positive for yeasts between June and October 2024 was conducted. DGD (ETEST (R)) was performed directly from blood culture broth and compared with SYO. The antifungal agents evaluated were anidulafungin, micafungin, caspofungin, fluconazole, voriconazole, and amphotericin B. Categorical agreement (CA) and essential agreement (EA) were analyzed. Results: A total of 32 Candida isolates were included. Overall CA was 90%, whereas EA was 60.6%. CA was 100% for amphotericin B, 92.5% for azoles, and 86% for echinocandins. No very major errors were observed. However, all Candida parapsilosis isolates showed major errors for anidulafungin, appearing resistant by DGD and susceptible by SYO. All DGD results were interpretable after 24 hours. Conclusions: DGD performed directly from positive blood culture bottles provides early antifungal susceptibility results with high CA and markedly reduced turnaround time. However, caution is required when interpreting anidulafungin resistance in C. parapsilosis. This approach may serve as an adjunctive tool for early optimization of antifungal therapy.
Introduction: Early appropriate antimicrobial therapy is a key determinant of outcome in sepsis, yet conventional urine culture takes 24–48 hours. We evaluated the clinical impact of a rapid microbiological algorithm applied directly to urine, combined with antimicrobial stewardship, in patients with suspected urinary sepsis. Methods: Prospective quasi-experimental two-phase cohort study at a tertiary hospital. In adults with simultaneous urine and blood cultures, an initial observational phase formed the comparison cohort (conventional culture), and a second phase the intervention cohort, in which urine underwent Gram stain, laser-nephelometry growth detection (Alfred 60/AST), MALDI-TOF-MS identification, rapid susceptibility testing, and immunochromatographic ESBL and carbapenemase detection, with immediate reporting and recommendations by an infectious diseases specialist. Multivariable models (logistic and negative binomial) were adjusted for age, sex, Charlson index, department and qSOFA. Results: We included 594 patients (297 per cohort). The algorithm achieved organism identification in 92.6% of cases, with a median turnaround time of 7.25 versus 75.0 hours (p<0.001), and 98.6% agreement with culture. Overall mortality was 6.1% versus 11.1% (p=0.039). After adjustment, the intervention was associated with significant reductions in hospital stay (IRR 0.82; p=0.012), days of therapy (IRR 0.79; p<0.001), intravenous antibiotics (IRR 0.83; p=0.001), need for ICU admission (OR 0.42; p=0.003) and overall mortality (OR 0.44; p=0.011). Conclusions: A rapid urine diagnostic algorithm, integrated with an expert stewardship intervention, was associated with lower antibiotic consumption and improved outcomes in suspected urinary sepsis. Combining rapid diagnostics with expert advice appears key to translating microbiological information into effective therapeutic decisions.
Introducción: La monitorización terapéutica de los niveles plasmáticos de antibióticos beta-lactámicos para el ajuste de dosis y la consecución de objetivos farmacocinéticos/farmacodinámicos es una estrategia destinada a optimizar la dosificación en pacientes críticos y en pacientes con características especiales. El objetivo de este estudio es describir la actividad llevada a cabo durante el año 2023 en nuestro hospital, en colaboración con todos los departamentos clínicos implicados: el Servicio de Análisis Clínicos (Farmacocinética y Microbiología), el Servicio de Farmacia y la Unidad Territorial de Infección Nosocomial, en el marco de un Programa de Optimización de Antimicrobianos. Métodos: Estudio retrospectivo observacional descriptivo sobre la aplicación de la monitorización terapéutica de betalactámicos. Los clínicos solicitan una interconsulta al Servicio de Farmacia para iniciar la monitorización terapéutica de los niveles plasmáticos de betalactámicos. Una vez que el paciente alcanza el estado estacionario, se obtiene una muestra de sangre. Si se realizan ajustes de dosis, se vuelve a medir el nivel plasmático tras 24-48 horas. Todas las determinaciones de niveles plasmáticos realizadas durante 2023 se registraron en una hoja de cálculo Excel, junto con las modificaciones del tratamiento derivadas de los niveles plasmáticos medidos. Se definió un nivel óptimo como una concentración cuatro veces superior a la concentración mínima inhibitoria (CMI) del microorganismo causante sin alcanzar niveles tóxicos. Resultados: Se realizaron un total de 717 determinaciones en 487 pacientes; el 43,3% ingresaron en la Unidad de Cuidados Intensivos, mientras que el resto estaban hospitalizados en otros servicios. Se realizaron ajustes de dosis en el 34,6% de los pacientes críticos, en comparación con el 32,6% en los pacientes no críticos. En el 79.3% de los pacientes con aislamientos microbiológicos, se alcanzó el objetivo terapéutico de mantener concentraciones libres del fármaco por encima de la CMI del patógeno. Conclusión: La monitorización terapéutica de los niveles plasmáticos de betalactámicos podría ser una herramienta útil para la optimización de la dosis y la consecución de los niveles plasmáticos óptimos.